Upstream Bio, Inc. (UPB) – What Are Brokerages Thinking About This Stock?

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have earned an average recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $26.67.

A number of equities research analysts recently issued reports on UPB shares. Weiss Ratings raised Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Truist Financial dropped their price objective on Upstream Bio to $25.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. HC Wainwright cut their price objective on Upstream Bio to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Wall Street Zen lowered Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, JPMorgan Chase & Co. lifted their target price on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th.

Upstream Bio Stock Down 2.8%

NASDAQ:UPB traded down $0.08 during mid-day trading on Friday, hitting $2.78. 891,335 shares of the stock traded hands, compared to its average volume of 1,350,694. The stock has a market capitalization of $152.37 million, a price-to-earnings ratio of -0.92 and a beta of 1.60. Upstream Bio has a 52 week low of $2.68 and a 52 week high of $33.68. The firm’s 50 day moving average is $4.24 and its two-hundred day moving average is $8.10.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Tuesday, November 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.55 million. Upstream Bio had a negative net margin of 5,712.33% and a negative return on equity of 57.09%. As a group, research analysts predict that Upstream Bio will post -2.81 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in UPB. Public Employees Retirement System of Ohio bought a new stake in Upstream Bio during the 2nd quarter valued at about $33,000. Persistent Asset Partners Ltd purchased a new stake in Upstream Bio in the 2nd quarter valued at about $34,000. Hsbc Holdings PLC purchased a new stake in Upstream Bio in the 2nd quarter valued at about $78,000. Voya Investment Management LLC bought a new position in Upstream Bio in the 3rd quarter worth about $57,000. Finally, Canada Pension Plan Investment Board bought a new position in Upstream Bio in the 2nd quarter worth about $80,000.

About Upstream Bio

Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.